“In a world where we have so many wearables — smart rings, watches, glucose sensors — it’s challenging to integrate all of this information,” say Biolinq founder Jared Tangney and CEO Rich Yang. “So we decided to make it available to everybody in one device.” In this Vanguards of Health Care episode, the pair speak with Bloomberg Intelligence’s analyst Matt Henriksson about Biolinq’s microsensor-based patch that uses silicon semiconductor technology to track glucose and potentially other biomarkers. They also discuss the company’s commercial strategy for type 2 diabetes patients following its FDA de Novo approval, a US regulatory designation granted to first-of-its-kind medical devices that have been shown to be safe and effective.

See omnystudio.com/listener for privacy information.